A Tale from the Dusty Corner: ProQR Therapeutics N.V (PRQR) Stock

Chardan Capital Markets raised the price target for the ProQR Therapeutics N.V (NASDAQ:PRQR) stock from “a Neutral” to “a Buy”. The rating was released on November 08, 2023, according to finviz. We previously noted in another research note published on March 30, 2023 by JMP Securities that upgraded the stock from a Mkt perform to a Mkt outperform with a price target of $5 for PRQR stock. The research report from Cantor Fitzgerald has upgraded the stock from Neutral to Overweight, with a price target set at $5. The stock was downgraded by Citigroup, who disclosed in a research note on February 14, 2022, from Buy to Neutral and set the price objective to $1.70. In their research brief published February 11, 2022, Stifel analysts downgraded the ProQR Therapeutics N.V stock from Buy to Hold with a price target of $3.

Historical Earnings Surprises and Revenue Forecasts

Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$0.08 during the last quarter as opposed to a consensus estimate of $0.01, which indicates the company missed its estimate by -$0.09, which implies that the company surprised the market by -900.00%. It appears that the average earnings per share estimate for the current quarter (ending in Mar 2024) is -$0.11. This is an average of 5 analysts’ earnings, where the high earnings per share estimate is -$0.08 and the low earnings per share estimate is -$0.17.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The latest trade, Performances and Moving Averages give us the following Picture

The firm’s stock price fluctuated -4.59% within the last five trades and 14.50% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 65.93% in the last 6 months and 13.93% was added to its value over the previous 3 months. PRQR stock is trading at a margin of 3.02%, 6.72% and 31.75% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

As of the close of trading, PRQR deals in the Healthcare domain. The stock is trading -37.26 percent below its 52-week high and 106.30 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 20.17. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does ProQR Therapeutics N.V’s Profitability and Valuation Ratios Tell Us About the Stock?

With regard to the profitability of the company, the operating margin is currently at -535.55 percent and the profit margin is -431.93 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.

The stock’s market cap achieved a total value of $185.07 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 26.29 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 3.93, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 35.79 percent of ProQR Therapeutics N.V shares are owned by insiders, and 23.67 percent are held by financial institutions.

Most Popular

Related Posts